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Activation of complement by hemodialysis membranes: Polyacryloni-
true binds more C3a than cuprophan. Conventionally, complement
activation by hemodialysis membranes has been determined by mea-
suring fluid phase C3a. Based on such measurements, polyacrylonitrile
(PAN) membranes have been classified as weak activators compared to
cuprophan. Previous studies have demonstrated, however, that PAN
adsorb fluid phase C3a. Based on that observation, we hypothesized
that complement activation by PAN might be artifactually underesti-
mated if relatively large amounts of C3a remained membrane bound. In
the present study, a method that allows the simultaneous quantification
of both fluid phase and membrane bound C3a was used to assess
complement activation by PAN and cuprophan. Pieces of membrane
were incubated with C3-depleted serum that had been repleted with
radiolabeled C3. Subsequently, the supernates and membranes were
subjected to SDS-PAGE, and complement activation was quantified by
determining the radioactivity of the C3a bands in the gel. The results
showed that while the serum exposed to cuprophan membranes con-
tained almost five times more C3a than that exposed to PAN, approx-
imately 80 times more C3a was bound to the PAN membranes.
Consequently, the total amount of C3a generated in the presence of
PAN was higher than that generated in the presence of cuprophan. We
conclude that assessment of complement activation by hemodialysis
membranes using fluid phase C3a measurements alone may be mislead-
ing.
Clinical hemodialysis is associated with activation of the
alternative pathway of complement (APC) [1—41 and generation
of C3a. During the past few years, determination of C3a
concentration in the dialyzer efferent plasma of patients under-
going hemodialysis has been used as a means of quantifying
complement activation. The validity of this approach, however,
requires that all of the C3a that is generated be available for
assay.
Based on the concentration of C3a present in the dialyzer
efferent plasma, cuprophan membranes have been classified as
potent activators and polyacrylonitrile (PAN) membranes as
weak activators of complement. It has been, however, sug-
gested that PAN has a greater affinity for C3a than cuprophan
[5]. If the majority of generated C3a were bound to PAN and
only a relatively small portion of the C3a could be detected in
the efferent plasma, complement activation would be underes-
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timated. In order to determine complement activation more
accurately, an assay has been developed that allows quantita-
lion of both fluid phase C3a and membrane associated C3a.
Using this assay, we found that the total amount of C3a that was
generated when serum was incubated in the presence of PAN
was greater than that generated in the presence of cuprophan
membranes.
Methods
Buffers and solutions
The following buffers and solutions were used: phosphate-
buffered saline, consisting of 10 m sodium phosphate and 145
mM NaCI, pH 7.4 (PBS); veronal buffered saline consisting of
0.1% gelatin, 140 mivi NaCI and 5 m sodium barbital, pH 7.4
(GVB); GVB containing 0.15 mri CaCI2 and 0.5 mrvi MgCI2
(GVB )
Hemodialysis membranes
PAN membrane (Biospal®, AN69S), a copolymer of poly-
acrylonitrile and sodium methallyl sulfonate, was obtained in
sheet format from Hospal Medical Corporation (East Bruns-
wick, New Jersey, USA). The cuprophan membrane was
supplied in sheet format by Drs. Baurmeister and Vienken
(Akzo, formerly Enka, Wuppertal, FRG). Circular discs of
these membranes with a diameter of 0.6 cm were washed three
times with PBS prior to use in all experiments.
C3-depleted serum and C3
C3-depleted serum was prepared from normal human serum
(NHS) by using immunoaffinity chromatography as previously
described [6]. C3 was isolated from NHS by published proce-
dures [61 and was radiolabeled with 125! as Nal (Amersham
Corp., Arlington Heights, Illinois, USA) by using Enzymo-
beads (BioRad Laboratories, Richmond, California, USA). The
specific activity of the radiolabeled C3 was 0.15 to 0.30 x l0
cpm//Lg. There was no loss of functional activity as assessed by
hemolytic assay [6]. Purified C3a, provided by Dr. Tony Hugh
(Scripps Institute, La Jolla, California, USA), was radiolabeled
as described above to a specific activity of -'-0.4 x 106 cpm/g.
Incubation of '251-C3-containing serum with membranes
C3-depleted serum repleted with radiolabeled C3 (750 tgIml)
was diluted 1:3 (voh/vol) with GVB. An ahiquot of 50 d of the
mixture was incubated with one circular disc of either cu-
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prophan or PAN membrane at 37°C in a 12 x 75 mm borosili-
cate glass tube (American Scientific Products, McGaw, Illi-
nois). After 30 minutes, the membrane was transferred to a
separate previously unused tube and the membrane associated
radioactivity was quantified in a gamma counter. Next, the
membrane and a 10 pJ aliquot of corresponding serum sample
were prepared and subjected to polyacrylamide gel electropho-
resis in the presence of sodium dodecyl sulfate (SDS-PAGE) as
described below.
SDS-PAGE analysis
Serum samples (10 1d each) or membrane discs were mixed
with sample buffer that consisted of 0.125 M Tris-HCI, pH 6.8,
1% SDS, 2.5% 2-mercaptoethanol and 10% glycerol (final
concentrations). The tubes containing the samples were incu-
bated in a boiling water bath. After five minutes, the contents of
the tubes (including the membrane disc where appropriate)
were placed into the wells of the stacking gel, and the proteins
were separated in a 6 to 15% gradient gel [7]. After completion
of the electrophoresis, the membrane disc was recovered and
the residual membrane associated radioactivity was deter-
mined. In order to calculate the efficiency of removal of
membrane bound C3-related peptides, the following formula
was used:
(pre-elution cpm) — (post-elution cpm)
percent elution (pre-elution cpm)
x 100
The gels were fixed, stained with Coomassie Brilliant Blue
R-250 (BioRad Laboratories, Richmond, California, USA) and
destained. Gels were prepared in duplicate. To assess the forms
of C3 that were present in the fluid phase and those that were
bound to the membrane, an autoradiograph was prepared from
one gel [8]. The other gel was used for C3a quantitation as
described below.
Quantitation of C3a
In order to quantitate C3a in the sample, the C3a-containing
band was excised from the second gel and the radioactivity was
determined in a gamma counter. Localization of the C3a band
was facilitated by adding non-radioactive low molecular weight
protein standards (BioRad) to each lane. To control for nonspe-
cific radioactivity, membrane discs were incubated with 1251
C3-containing serum chelated with EDTA (10 m final concen-
tration). Sections of the gel corresponding to the position of C3a
were excised from the control gels and the radioactivity was
determined. This value was subtracted in order to define the
amount of C3a generated in the presence of the membranes.
In order to assess the reliability of this method as a means of
quantitating C3a, '251-C3-containing serum was incubated with
200 d of cobra venom factor-containing C3 convertase
(CVFBb) and 110 jd of GVB at 37°C [9]. After 60 minutes,
incremental amounts of the reaction mixture were subjected to
SDS-PAGE and C3a was quantified by excising the appropriate
portion of the gel as described above.
Statistical analyses
Unpaired data were analyzed by the two-tailed (-test of
Student, and P values <0.05 were considered to be statistically
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Fig. 1. Auroradiograph showing C3 and C3-derived polypeptides in
serum after incubation with hemodialysis membranes, C3-depleted
serum that had been repleted with radiolabeled C3 was incubated with
a circular disc of either cuprophan or PAN membrane, and aliquots of
the treated serum (supernate) were subsequently subjected to SDS-
PAGE. Lane a, radiolabeled C3a; lane b, serum incubated with the
cuprophan membrane; lane c, serum incubated with the PAN mem-
brane. The positions of the molecular weight standards are indicated on
the left, and the positions of some of the known C3-related polypeptides
are shown on the right. The C3a band is conspicuous in the lane
containing the serum incubated with cuprophan and is barely visible in
the lane containing the serum incubated with PAN.
significant. Linear regression analysis was performed by using
the method of least mean squares.
Results
Efficiency of removal of membrane bound C3 by
electroelution
During SDS-PAGE, 94 2% (N = 5) and 99 1% (N = 5) of
the radiolabeled C3 and C3-derived peptides were eluted from
the cuprophan and PAN membranes, respectively.
Analysis of serum C3 after exposure to membranes
Activation and degradation products of C3 were present in
the serum samples after incubation with either cuprophan or
PAN (Fig. 1). A prominent C3a band (M — 9k Da) was seen in
the serum incubated with cuprophan (Fig. 1, lane b). In the
PAN treated serum, the C3a band was barely visible (Fig. 1,
lane c).
Analysis of C3 eluted from membranes
The C3 eluted from membranes after incubation with serum
was also analyzed by using SDS-PAGE. The 3 chain of C3 and
faint bands with Mr> 200 kDa (probably representing multi-
mers derived from the a chain of C3b or C3ba bound covalently
to plasma proteins [10]) were present in the eluate from cu-
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Fig. 3. Relationship between the amount of activated C3 electro-
phoresed and the recovery of C3a. Aliquots of C3-depleted serum
containing radiolabeled C3 were incubated with the cobra venom
factor-containing C3 convertase CVFBb and subsequently incremental
amounts of the reaction mixture were subjected to SDS-PAGE. The
region of the gel containing C3a was excised and radioactivity was
determined. The linearity of the relationship (r = 0.99) indicates that
C3a recovery was consistent.
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Fig. 4. Generation of C3a during incubation of serum with cuprophan
or PAN membranes. Radiolabeled C3 was incubated with C3-depleted
serum and pieces of cuprophan or PAN membrane. Serum proteins in
the supernate and those bound to membrane were subjected to SDS-
PAGE. C3a was quantitated by determining the radioactivity of the C3a
band. The bars (open for cuprophan, hatched for PAN) depict the mean
SEM (N = 5). *The difference between cuprophan and PAN was
statistically significant (P < 0.001).
was greater than that generated in the presence of cuprophan
membranes (8,744 415 cpm vs. 4,955 202 cpm, N 5, P <
0.001).
Discussion
The complement activating capacity of PAN membranes has
been controversial. Clinical hemodialysis using this membrane
has been shown to induce a 25% reduction in the total hemolytic
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FIg. 2. Autoradiograph of C3 and C3-related peptides elated from
cuprophan or PAN membranes. The membranes after incubation with
C3-depleted serum and radiolabeled C3 were washed three times with
PBS and then subjected to SDS-PAGE. Lane a, purified C3a; lane b,
eluate from cuprophan; lane c, eluate from PAN. The positions of the
molecular weight standards are indicated on the left, and the positions
of some of the known C3-related polypeptides are shown on the right.
The C3a band is invisible in the eluate from cuprophan (lane b) but is
prominent in the eluate from PAN (lane C).
prophan (Fig. 2, lane b). These high molecular weight C3-
containing polypeptides were more conspicuous in the eluate
from PAN. As evidenced by the presence of the a chain of C3,
the PAN membranes also bound unactivated C3. In addition,
the a68 fragment of iC3b and the a43 fragment of iC3b, C3c or
both, were observed (Fig. 2, lane c). A C3a band was prominent
in the eluate from PAN but was invisible in the eluate from the
cuprophan membrane.
Quantitation of C3a in the treated sera (supernates) and
eluates from membranes
There was a linear relationship between the amount of
activated '251-C3 that was applied to the gels and the amount of
radioactivity present in the C3a band (Fig. 3). These results
indicated that recovery of C3a from the gels was quantitative.
Following incubation with cuprophan membranes, serum
samples contained 4.7 times more C3a than the serum samples
incubated with PAN (4,862 204 cpm vs. 1,041 143 cpm, N
= 5, P < 0.001; Fig. 4). In contrast, much greater amounts of
C3a were eluted from the PAN membrane than from the
cuprophan membrane (7,707 533 cpm vs. 93 9 cpm, N = 5,
P < 0.001). Consequently, the total amount of C3a (supernate +
membrane associated) generated in the presence of the PAN
*
*
0
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activity of plasma complement (CH5O), and a comparable
reduction in CH5O was observed during dialysis with cuprophan
membranes [11]. This decrease in CH5O suggested that, like
cuprophan, PAN was a potent complement activator. Plasma
concentrations of C3adesArg, however, argued against this hy-
pothesis. The peak concentration of this polypeptide in the
dialyzer efferent plasma was approximately 10 times higher
during hemodialysis with cuprophan when compared to dialysis
with PAN [2]. In agreement with this observation, our present
study showed that there was significantly more (4.7 times) C3a
in the serum treated with cuprophan than in the PAN treated
serum (Fig. 4).
Previous in vitro studies have suggested, however, that PAN
membranes adsorbed C3adesArg [5]. The present study has
provided quantitation of the adsorbed C3a protein and demon-
strated that the vast majority of the C3a molecules generated in
the presence of PAN remained bound to the membrane surface
(Fig. 4). We have also performed experiments in which PAN
and cuprophan membranes were incubated with normal human
serum instead of C3-depleted serum containing radiolabeled C3.
Membrane associated proteins were eluted by using 6M guani-
dine. The amount of C3a present in the serum and the mem-
brane eluates was subsequently quantified by using a radioim-
munoassay. The results obtained using this method (data not
shown) were similar to those depicted in Figure 4. Together
these experiments show that complement activation by PAN
would be markedly underestimated if only fluid phase C3a were
measured.
Based on the present data, it seems plausible to suggest that
the decrease in CHS0 following dialysis with PAN is due to two
mechanisms of complement consumption. First, complement is
activated (Fig. 4), and second, unactivated C3 is adsorbed onto
the PAN membrane (Fig. 2, lane C). The latter observation is in
agreement with that of Amadori et al. These investigators
reported that incubation of serum with PAN even in the
presence of EDTA (added to prevent complement activation)
resulted in a loss of serum hemolytic activity [12].
Contrary to the clinical hemodialysis setting, continuous
rapid fluid flow was absent in the experiments reported herein.
Accordingly, the proportion of C3a bound to PAN membranes
during clinical dialysis may be less than that bound during the in
vitro incubation conditions used in our experiments. We have
observed, however, that even after repeated washing of the
serum-treated PAN membranes with PBS, only 26% of the
membrane bound C3a could be removed (data not shown). Thus
it seems reasonable to conclude that observations made using
our in vitro system apply to the clinical dialysis setting as well.
Since anionic methallyl sulfonate groups are present on the
surface of PAN, and since C3a is a basic peptide (p1 -9.5) [13],
binding of this peptide to PAN is likely to be mediated by ionic
interactions.
Although PAN adsorbed more C3 and C3-derived polypep-
tides than did cuprophan (Fig. 2), there appeared to be relative
specificity for this adsorption. The affinity of C3a to PAN was
much greater than that of unactivated C3. The difference was
particularly striking considering the fact that C3a has relatively
fewer tyrosine residues and is therefore less susceptible to
iodination than the remaining portion of the C3 molecule [14,
15]. The lower affinity of native C3 for PAN may, in part, be
attributed to the acidic nature of this protein (p1 5.7) [16].
In studies analogous to those reported herein, C5a (p1 —8.5)
binding to PAN was also observed to be much greater than to
cuprophan (data not shown). Conceivably, binding of C5a could
improve the biocompatibility of PAN membranes by reducing
the concentration of plasma C5a (the mediator of hemodialysis
associated leukoagglutination). Alternatively, membrane asso-
ciated anaphylatoxins could initiate an inflammatory response
by stimulating adherent granulocytes and monocytes.
Complement activating potential is an important criterion
used to determine the biocompatibility of dialyzers and other
biomaterials. The studies reported herein have shown that an
accurate assessment of complement activation requires a quan-
titative and qualitative analysis of both plasma and surface
associated C3 and its fragments.
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